Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Sees Significant Drop in Short Interest

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) was the recipient of a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 27,000 shares, a decline of 63.6% from the July 30th total of 74,099 shares. Based on an average trading volume of 50,747 shares, the short-interest ratio is currently 0.5 days. Currently, 0.2% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. HC Wainwright assumed coverage on Radiopharm Theranostics in a report on Thursday, June 4th. They issued a “buy” rating and a $6.00 price target for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Radiopharm Theranostics has a consensus rating of “Hold” and a consensus price target of $11.00.

Radiopharm Theranostics Stock Performance

Shares of RADX traded up $0.15 during midday trading on Friday, hitting $2.41. The stock had a trading volume of 333,279 shares, compared to its average volume of 59,357. The company has a 50 day simple moving average of $3.51 and a two-hundred day simple moving average of $4.23. Radiopharm Theranostics has a twelve month low of $2.04 and a twelve month high of $16.25.

Radiopharm Theranostics (NASDAQ:RADX) last posted its quarterly earnings data on Friday, July 31st. The company reported ($0.81) earnings per share for the quarter. The firm had revenue of $0.49 million during the quarter. Equities analysts expect that Radiopharm Theranostics will post -2.36 EPS for the current fiscal year.

Institutional Trading of Radiopharm Theranostics

A number of hedge funds and other institutional investors have recently made changes to their positions in RADX. Hsbc Holdings PLC bought a new stake in shares of Radiopharm Theranostics in the fourth quarter worth $1,007,000. Virtu Financial LLC bought a new position in Radiopharm Theranostics in the fourth quarter valued at $76,000. Jane Street Group LLC acquired a new stake in Radiopharm Theranostics in the 4th quarter valued at $76,000. Finally, Marex Group plc bought a new stake in Radiopharm Theranostics during the 4th quarter worth about $54,000.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.